Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of NYSE OGEN opened at $0.30 on Monday. The firm’s fifty day moving average is $0.51 and its two-hundred day moving average is $1.08. Oragenics has a 52-week low of $0.28 and a 52-week high of $7.74. The company has a market cap of $1.66 million, a P/E ratio of -0.04 and a beta of 0.49.

Oragenics (NYSE:OGEN) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new stake in Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent filing with the Securities and Exchange Commission (SEC). 18.71% of the stock is currently owned by institutional investors and hedge funds.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.